Начало › Остра миелоидна левкемия › Мериленд › Baltimore
Клинични проучвания за Остра миелоидна левкемия в Baltimore, MD
19 проучвания за Остра миелоидна левкемия търсят участници в обекти в и около Baltimore (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Набиране на участнициФаза 2
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Набиране на участнициРанна фаза 1
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Набиране на участнициНаблюдателно проучванеЗдравите доброволци са добре дошли
- Mercy Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- и още 2
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Набиране на участнициФаза 1
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Набиране на участнициФаза 2
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
Набиране на участнициФаза 1/2
- Johns Hopkins University, Baltimore
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Набиране на участнициФаза 3
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Набиране на участнициФаза 2
- John Hopkins School of Medicine, Baltimore
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Набиране на участнициФаза 3
- US-Baltimore MD-UMGCCC, Baltimore
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Набиране на участнициФаза 3
- US-Baltimore MD-UMGCCC, Baltimore
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Набиране на участнициФаза 1/2
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
Набиране на участнициФаза 1
- University of Maryland/Greenebaum Cancer Center, Baltimore
Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
Набиране на участнициФаза 1
- Tania Jain, MD, Baltimore
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Набиране на участнициФаза 3
- University of Maryland Medical Center (UMMC), Baltimore
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Набиране на участнициНаблюдателно проучване
- Johns Hopkins, Baltimore
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
Набиране на участнициФаза 2
- University of Maryland Greenebaumn Comprehensive Cancer Center, Baltimore
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Набиране на участнициФаза 1/2
- Sibley Memorial Hospital, Baltimore
- University of Maryland, Baltimore
- Johns Hopkins Main Center, Baltimore
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Набиране на участнициФаза 1
- Johns Hopkins School of Medicine, Baltimore
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Набиране на участнициЗдравите доброволци са добре дошли
- Johns Hopkins University, Baltimore
Проучвания за Остра миелоидна левкемия в други градове
- Houston, TX85 проучвания
- New York City, NY51 проучвания
- Boston, MA44 проучвания
- Seattle, WA41 проучвания
- Baldwin Park, CA40 проучвания
- Columbus, OH35 проучвания
- Philadelphia, PA34 проучвания
- Durham, NC33 проучвания
- Atlanta, GA31 проучвания
- Tampa, FL29 проучвания
- Chicago, IL26 проучвания
- Portland, OR25 проучвания
Други проучвания в Baltimore
- Рак на белия дроб с недребноклетъчен тип60 проучвания
- Рак на гърдата47 проучвания
- Рак на простатата43 проучвания
- Рак на белия дроб40 проучвания
- Рак (всички видове)37 проучвания
- Рак на панкреаса31 проучвания
- Колоректален рак31 проучвания
- Метастатичен рак28 проучвания
- Затлъстяване26 проучвания
- Рак на пикочния мехур24 проучвания
- Сърдечна недостатъчност24 проучвания
- Рак на яйчниците22 проучвания
От ClinicalTrials.gov, данни към 6.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.